UNSPSC 51352420: Etonogestrel and ethinyl estradiol combination

This classification denotes a combination contraceptive drug. The first component of this drug is etonogestrel, a therapeutic progestin with the molecular formula C22H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304GTH6RNH, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- but generally known as etonogestrel, which bears US NIH Compound Identifier 40976.

UNSPSC 51352420 Etonogestrel and ethinyl estradiol combination is a Commodity code covering a specific combination contraceptive product that state and local governments procure primarily through their pharmacy benefit programs, cooperative purchasing alliances, and health plans. Recent solicitations show state agencies and cooperative purchasing organizations acquiring this product as part of broader generic pharmaceutical and over-the-counter product agreements, rather than as a standalone item; it appears within multi-product pharmacy catalogs distributed through established pharmaceutical wholesalers. The issuing bodies include state health and human services agencies and multistate cooperative purchasing consortia that aggregate demand across multiple state and local facilities. Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the types of buyers actively seeking pharmacy suppliers under this code, with MMCAP drawing participation from multiple states including Oregon.

Geographic activity centers on Texas and Minnesota, with MMCAP's cooperative structure extending reach across additional state and local systems. The Minnesota Department of Administration's Office of State Procurement issued an RFP (Solicitation S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline, seeking manufacturers to supply generic multi-source pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026 and a two-year contract term. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking to establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Both solicitations require cGMP and Drug Supply Chain Security Act compliance, with MMCAP's RFP weighting price competitiveness at 75 percent of evaluation and imposing a 3 percent administrative fee on all contract purchases.